Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 216

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Zidovudine in Persons with Asymptomatic HIV Infection and CD4+ Cell Counts Greater than 400 per Cubic Millimeter

Open access
Cooper, David A., Gatell, Jose M., Kroon, Susanne, Clumeck, Nathan, Millard, Judith, Goebel, Frank-D, Bruun, Johan N., Stingl, Georg, Melville, Rex L., Gonzalez-Lahoz, Juan, Stevens, John W., Fiddian, A. Paul·1993·New England Journal of Medicine

Abstract

BACKGROUND: Zidovudine therapy is of benefit in the treatment of symptomatic and asymptomatic human immunodeficiency virus (HIV) infection in persons with CD4+ cell counts of less than 500 per cubic millimeter. The efficacy, safety, and duration of benefit of zidovudine in those with 500 or more CD4+ cells per cubic millimeter are uncertain. METHODS: In a double-blind, placebo-controlled trial, 993 patients with asymptomatic HIV infection and CD4+ cell counts above 400 per cubic millimeter were randomly assigned to receive zidovudine (500 mg twice daily) or placebo for three years. The primary end point was progression of disease, as defined by the development of Centers for Disease Control and Prevention (CDC) group IV disease (including recurrent oral candidiasis, hairy leukoplakia, or progressive diarrhea) or two CD4+ cell counts below 350 per cubic millimeter. This outcome measure was changed from the original end point of the acquired immunodeficiency syndrome (AIDS) or advanced AIDS-related complex to reflect changes in recommendations for management. The study was terminated after the first interim analysis. RESULTS: Disease progression was significantly less frequent in the zidovudine group (relative risk, 0.56; 95 percent confidence interval, 0.43 to 0.75; P < 0.001 by the log-rank test). The probability of disease progression at two years was 0.19 with zidovudine, as compared with 0.34 with placebo (95 percent confidence interval for the difference, -0.21 to -0.08). Progression to CDC group IV disease was reduced by half in the zidovudine recipients (relative risk, 0.49; P = 0.049) and decline in CD4+ cell counts to below 350 per cubic millimeter was reduced by 40 percent (relative risk, 0.60; P < 0.001). The inclusion of early HIV disease events (oral candidiasis, oral hairy leukoplakia, and herpes zoster) as end points confirmed the effects of zidovudine on the progression of clinical disease (relative risk, 0.55; 95 percent confidence interval, 0.37 to 0.84; P = 0.004). The median duration of treatment was 94 weeks. Severe hematologic or clinical side effects were rare. CONCLUSIONS: Treatment with zidovudine benefits HIV-infected persons with CD4+ cell counts above 400 per cubic millimeter. Despite the use of doses larger than those now generally prescribed, zidovudine was well tolerated for up to three years by most of our patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejm199307293290501

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 216

Metadata

Authors
Cooper, D. A., Gatell, J. M., Kroon, S., Clumeck, N., Millard, J., Goebel, F.-D., Bruun, J. N., Stingl, G., Melville, R. L., Gonzalez-Lahoz, J., Stevens, J. W., & Fiddian, A. P.
Venue
New England Journal of Medicine
Published
1993-07-29
Volume
329
Issue
5
Pages
297-303
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2116712233
Cited by
216
References
1
FWCI
36.85
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Zidovudine in Persons with Asymptomatic HIV Infection and CD4+ Cell Counts Greater than 400 per Cubic Millimeter. https://app.cochat.ai/papers/10.1056/nejm199307293290501
The paper
Cooper, D. A., Gatell, J. M., Kroon, S., Clumeck, N., Millard, J., Goebel, F.-D., Bruun, J. N., Stingl, G., Melville, R. L., Gonzalez-Lahoz, J., Stevens, J. W., & Fiddian, A. P. (1993). Zidovudine in Persons with Asymptomatic HIV Infection and CD4+ Cell Counts Greater than 400 per Cubic Millimeter. New England Journal of Medicine. https://doi.org/10.1056/nejm199307293290501

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.